{"id":808889,"title":"Use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: NACI recommendations: Economic evidence supplementary appendixrecommendations. - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-02-10","captureTimestamp":"2026-02-10T01:15:13.179000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html","snippet":"Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix Download in PDF format (1.93 MB, 44 pages) Organization: Public Health Agency of Canada Cat.: HP5-154/2023E-PDF ISBN:…","rawSnapshotUrl":"/api/snapshots/raw/808889","browseUrl":"https://replay.healtharchive.ca/job-7/20260210011513/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html#ha_snapshot=808889","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}